Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

NCT00743067 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00743067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00743067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
August 9, 2006
Completion date
November 9, 2009
Enrollment
37 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours